Insider Transactions in Q1 2024 at Exact Sciences Corp (EXAS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 21
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
415
-5.64%
|
$25,315
$61.5 P/Share
|
|
Feb 21
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
1,078
-11.07%
|
$65,758
$61.5 P/Share
|
|
Feb 21
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
895
-9.21%
|
$54,595
$61.5 P/Share
|
|
Feb 21
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,079
-1.48%
|
$65,819
$61.5 P/Share
|
|
Feb 21
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
4,975
-0.4%
|
$303,475
$61.5 P/Share
|
|
Feb 21
2024
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
706
-1.61%
|
$43,066
$61.5 P/Share
|
|
Feb 21
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,493
-28.73%
|
$91,073
$61.5 P/Share
|
|
Feb 20
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
864
+10.51%
|
-
|
|
Feb 20
2024
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+18.76%
|
-
|
|
Feb 20
2024
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,729
+15.1%
|
-
|
|
Feb 20
2024
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+3.0%
|
-
|
|
Feb 20
2024
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,374
+0.83%
|
-
|
|
Feb 20
2024
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+4.88%
|
-
|
|
Feb 20
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,112
+37.46%
|
-
|
|
Feb 15
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
421
-6.09%
|
$25,681
$61.43 P/Share
|
|
Feb 15
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
966
-11.43%
|
$58,926
$61.43 P/Share
|
|
Feb 15
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
965
-1.35%
|
$58,865
$61.43 P/Share
|
|
Feb 15
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
14,791
-1.19%
|
$902,251
$61.43 P/Share
|
|
Feb 15
2024
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
1,376
-3.2%
|
$83,936
$61.43 P/Share
|
|
Feb 15
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,888
-47.53%
|
$115,168
$61.43 P/Share
|
|
Feb 14
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
883
+11.32%
|
-
|
|
Feb 14
2024
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
2,031
+19.37%
|
-
|
|
Feb 14
2024
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,031
+2.76%
|
-
|
|
Feb 14
2024
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,133
+2.45%
|
-
|
|
Feb 14
2024
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
3,972
+8.46%
|
-
|
|
Feb 14
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,972
+50.0%
|
-
|
|
Jan 02
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
879
-9.91%
|
$64,167
$73.5 P/Share
|
|
Jan 02
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,000
-2.8%
|
$146,000
$73.5 P/Share
|